All In Biotech

Drug Trial Radar · NCT07862530

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

Phase II Trial of Neoadjuvant RP2 + Nivolumab in Patients With Resectable Melanoma

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Feb 27, 2028

Study completion Dec 31, 2033

Sponsor

Lead sponsor
Yana NajjarAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Replimune, Inc.
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery. The two therapies that will be combined in this study are nivolumab and RP2. Nivolumab is a standard treatment for this type of cancer. Nivolumab targets and blocks a receptor called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 may activate T-cells to find and kill cancer cells. RP2 is a new treatment that is not yet FDA approved to treat this cancer. RP2 is a herpes simplex virus (a microscopic life form commonly known as the "cold sore virus") that has been changed in the laboratory to grow in and destroy cancer cells and to activate (turn on) the immune system to attack the cancer cells.

Conditions

  • MelanomaCutaneous Melanoma Resectable, Melanoma

Interventions

  • RP2 (vusolimogene oderparepvec)Drug

    RP2 (vusolimogene oderparepvec) RP2 will be injected directly into the tumor every 2 weeks for three doses before surgery.

  • NivolumabDrug

    Nivolumab will be administered by intravenous infusion at a dose of 240 mg every 2 weeks for 3 doses during the neoadjuvant period, followed by 480 mg every 4 weeks for 11 doses during the adjuvant period.

  • Definitive Surgical ResectionProcedure

    Participants will undergo definitive surgical resection of all clinically resectable melanoma lesions following completion of neoadjuvant treatment with RP2 and nivolumab. Surgery will be performed according to standard clinical practice and institutional guidelines. Resected tumor tissue and, where applicable, involved lymph nodes will be collected and evaluated for pathologic response and other study-related assessments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Pathologic Response Rate (MPR)Time frame: At the time of definitive surgery, approximately 8 to 10 weeks after initiation of neoadjuvant treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.